摘要
Background Durable polymers used for first-generation drug-eluting stents （DES） potentially contribute to persistent inflammation and late DES thrombosis. We report the first in human experience with the rapamycin-eluting biodegradable polymer coated cobalt-chromium FIREHAWK stent with abluminal groove. Methods A total of 21 patients with stable or unstable angina, or prior myocardial infarction, with single de novo native coronary stenoses 〈30 mm in length in vessel sizes ranging from 2.25 to 4.0 mm were enrolled. The primary endpoint was major adverse cardiac events （MACE） at 30 days defined as the composite of cardiac death, myocardial infarction （Q and non-Q）, or ischemia-driven target lesion revascularization. Secondary endpoints include device, lesion, and clinical success rates, 4-month in-stent late lumen loss by quantitative coronary angiography （QCA）, proportion of uncovered or malapposed stent struts by optical coherence tomograpphy （OCT） at 4 months, and MACE at 4, 12, 24 and 36-month follow-up. Results Device success was 95.7%, lesion and clinical success was 100.0%. There were no MACE events at 30 days. One patient died of non-cardiac hemorrhagic stroke 5 days after index procedure. At 4 months, in-stent late loss was （0.13±0.18） mm, and complete strut coverage was 96.2% by OCT with 0.1% strut malapposition. At 4-month follow-up there was no additional MACE events, and a single target vessel （non-target lesion） revascularization. Conclusions The FIREHAWK abluminal groove biodegradable polymer rapamycin-eluting stent demonstrated feasibility, safety and efficacy in this first in human experience. OCT findings indicated excellent stent strut coverage 4 months after implantation. Larger studies are required to confirm whether the early FIREHAWK stent results translate into longer term restenosis and thrombosis benefits.
Background Durable polymers used for first-generation drug-eluting stents （DES） potentially contribute to persistent inflammation and late DES thrombosis. We report the first in human experience with the rapamycin-eluting biodegradable polymer coated cobalt-chromium FIREHAWK stent with abluminal groove. Methods A total of 21 patients with stable or unstable angina, or prior myocardial infarction, with single de novo native coronary stenoses 〈30 mm in length in vessel sizes ranging from 2.25 to 4.0 mm were enrolled. The primary endpoint was major adverse cardiac events （MACE） at 30 days defined as the composite of cardiac death, myocardial infarction （Q and non-Q）, or ischemia-driven target lesion revascularization. Secondary endpoints include device, lesion, and clinical success rates, 4-month in-stent late lumen loss by quantitative coronary angiography （QCA）, proportion of uncovered or malapposed stent struts by optical coherence tomograpphy （OCT） at 4 months, and MACE at 4, 12, 24 and 36-month follow-up. Results Device success was 95.7%, lesion and clinical success was 100.0%. There were no MACE events at 30 days. One patient died of non-cardiac hemorrhagic stroke 5 days after index procedure. At 4 months, in-stent late loss was （0.13±0.18） mm, and complete strut coverage was 96.2% by OCT with 0.1% strut malapposition. At 4-month follow-up there was no additional MACE events, and a single target vessel （non-target lesion） revascularization. Conclusions The FIREHAWK abluminal groove biodegradable polymer rapamycin-eluting stent demonstrated feasibility, safety and efficacy in this first in human experience. OCT findings indicated excellent stent strut coverage 4 months after implantation. Larger studies are required to confirm whether the early FIREHAWK stent results translate into longer term restenosis and thrombosis benefits.
